Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer’s disease?
- Department of Psychology, University of Cambridge, Cambridge, UK
Alzheimer’s disease (AD) is a global epidemic. Unfortunately, we are still without effective treatments or a cure for this disease, which is having devastating consequences for patients, their families, and societies around the world. Until effective treatments are developed, promoting overall health may hold potential for delaying the onset or preventing neurodegenerative diseases such as AD. In particular, chronobiological concepts may provide a useful framework for identifying the earliest signs of age-related disease as well as inexpensive and noninvasive methods for promoting health. It is well reported that AD is associated with disrupted circadian functioning to a greater extent than normal aging. However, it is unclear if the central circadian clock (i.e., the suprachiasmatic nucleus) is dysfunctioning, or whether the synchrony between the central and peripheral clocks that control behavior and metabolic processes are becoming uncoupled. Desynchrony of rhythms can negatively affect health, increasing morbidity and mortality in both animal models and humans. If the uncoupling of rhythms is contributing to AD progression or exacerbating symptoms, then it may be possible to draw from the food-entrainment literature to identify mechanisms for re-synchronizing rhythms to improve overall health and reduce the severity of symptoms. The following review will briefly summarize the circadian system, its potential role in AD, and propose using a feeding-related neuropeptide, such as ghrelin, to synchronize uncoupled rhythms. Synchronizing rhythms may be an inexpensive way to promote healthy aging and delay the onset of neurodegenerative disease such as AD.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with severe amnesia and a variety of other cognitive and behavioral impairments. AD is the most common form of dementia, which is estimated to be affecting more than 44.4 million people worldwide, making dementia a global epidemic and one of the greatest public health challenges of the 21st century (Prince et al., 2013). There is an urgent need to develop effective interventions to prevent, delay the onset, and slow the progression of AD. Unfortunately, we are currently without beneficial treatments or a cure for this devastating disease.
The majority of research efforts are focused on identifying specific mechanisms of disease and developing compounds to target the underlying disease pathology. However, finding ways to promote overall health is arguably, just as important. For 60 to 70 years our body’s natural defenses are able to ward off disease progression. Once we reach an unknown threshold, our repair and clearance mechanisms- which slow with age- are no longer able to counteract the damage to our cells (Martinez-Vicente et al., 2005; Martinez-Vicente and Cuervo, 2007; Rattan, 2010). This slowing then results in intracellular accumulation of misfolded proteins that form toxic multimetric complexes. The progressive accumulation of toxic structures inside cells is one of the main molecular characteristics of aging and is associated with most neurodegenerative diseases, including AD (Martinez-Vicente and Cuervo, 2007; Rattan, 2010).
We need to find ways to shift this delicately poised boundary to slow the aging process, and postpone when age-related diseases become problematic. Even relatively small changes, that delay the onset and spread of AD and other age-related conditions, have the potential to make a big impact on the quality of life of patients and reduce the costs to society.
The slow progression of AD emphasizes the need to focus on health promotion and prevention (Gandy and DeKosky, 2013). In autosomal dominant AD, a longitudinal study showed that patients had pathophysiological changes in cerebrospinal fluid biochemical markers up to 25 years prior to symptom onset (Bateman et al., 2012). It is unclear whether the same timeline applies to patients who develop sporadic AD, but it is hypothesized that sporadic AD also takes over a decade to develop before the onset of symptoms (Gandy and DeKosky, 2013; Jack et al., 2013).
AD pathology does not disrupt memory functioning in isolation, there are wide-spread effects throughout the body affecting physiological processes such appetite, sleep patterns, emotional regulation, and sense of smell (Witting et al., 1990; Mok et al., 2004; Tabert et al., 2005; Cai et al., 2012). There is evidence to suggest that some of these symptoms, such as circadian dysfunction and weight loss, may preface the clinical onset of memory and executive functioning deficits (Buchman et al., 2005; Knopman et al., 2007; Coogan et al., 2013).
Chronobiological concepts may provide a useful framework for understanding the link between the early changes in feeding behavior and sleep patterns, and the development of age-related disease such as AD. Disturbances of daily sleep-wake behaviors are common in AD, and are a leading cause for institutional care of patients (Bianchetti et al., 1995), thus there is great potential for identifying inexpensive and effective interventions by studying the circadian system in AD.
Understanding the physiological changes that contribute to AD and finding ways to promote overall health requires a systems level approach. The following review will provide a brief introduction to the circadian system, its potential role in AD, and propose adopting what we know from the food-entrainment literature to evaluate the potential for using a feeding-related neuropeptide, such as ghrelin, to synchronize uncoupled rhythms. Synchronizing rhythms may be an inexpensive way to promote healthy aging and delay the onset of neurodegenerative disease such as AD.
Circadian rhythms refer to a complex and distributed system imposing a temporal architecture on physiology and behavior. These rhythms are generated by hierarchically organized central and peripheral oscillators entrained (i.e., synchronized) by periodic stimuli in the external environment or within the body.
Biological clocks maintain synchrony between cycles in the environment and our physiological processes and behavior, to ensure that daily peaks in energy metabolism, gastrointestinal tract motility, cardiovascular activity, endocrine secretion, body temperature, and cognitive processes occur at optimal times of the day (Panda et al., 2002; Reppert and Weaver, 2002; Kalsbeek et al., 2006; Schmidt et al., 2007; Gerstner and Yin, 2010; Waterhouse, 2010; Huang et al., 2011; Konturek et al., 2011). Coordinating internal processes with the external environment optimizes energy expenditure and may also provide an evolutionary or survival advantage by ensuring activities are performed at appropriate times of the day to find food and mating partners, and avoid predators (Panda et al., 2002; Schibler et al., 2003; Woelfle et al., 2004). Further selective advantage of the circadian clocks may also come from temporally separating incompatible intracellular processes, ensuring that specific proteins are expressed at ideal time points (Rey and Reddy, 2013).
The core clock machinery is self-sustaining and has an endogenous period that approximates 24 h. A zeitgeber (i.e., entraining cue) is required to synchronize rhythms to match the 24 h day and keep internal processes aligned with the external environment. Although several parameters change in the daily environment, such as light, temperature, and humidity, the daily light-dark cycle is considered the dominant zeitgeber.
In mammals, the master circadian pacemaker is the suprachiasmatic nucleus (SCN) of the hypothalamus, which is located dorsal to the optic chiasm (Weaver, 1998; Reppert and Weaver, 2002; Karatsoreos and Silver, 2007; Welsh et al., 2010). The SCN is directly entrained by light-dark cycles in the environment through intrinsically photoreceptive retinal ganglion cells (Figure 1; Berson et al., 2002).
Figure 1. A simplified model of the mammalian circadian system under normal conditions. The light-entrainable oscillator (LEO) is located in the suprachiasmatic nucleus (SCN) of the hypothalamus. The LEO is directly entrained by light-dark cycles in the environment through intrinsically photoreceptive retinal ganglion cells, and generates circadian rest-activity rhythms as well as other rhythms that entrain to the environmental light-dark cycles. The LEO-driven activity rhythms then influence the timing of feeding behavior, which entrains the food-entrainable oscillator (FEO). FEO then drives several neuroendocrine, autonomic, and physiological rhythms throughout the brain and peripheral nervous system. The FEO also sends feedback to the LEO to remain coupled. Under certain conditions when the LEO is dysfunctional, or under conditions of constant darkness, the FEO can drive rest-activity rhythms and other rhythms normally entrained by light.
Outside the SCN there are circadian oscillators in peripheral organs and tissues, regulating local cycles of gene expression, physiology, and metabolic rhythms (Yamazaki et al., 2000; Guilding and Piggins, 2007; Kornmann et al., 2007; Dibner et al., 2010). Rhythmic expression of clock-controlled genes (e.g., PER1,2, CRY1,2, CLOCK, BMAL1), which are produced by a series of interlocking transcriptional feedback/feedforward loops, drive physiological and behavioral rhythms (Reppert and Weaver, 2002). Through neural, hormonal, and behavioral outputs the SCN directly and indirectly coordinates this multioscillatory system, synchronizing rhythms throughout the central and peripheral nervous systems (Dibner et al., 2010). By having a master pacemaker (i.e., SCN) to align circadian gene oscillations within peripheral tissues, oscillators throughout the body remain coupled together, synchronizing cellular and physiological processes with daily cycles in the external environment.
When the SCN is unable to entrain to light-dark cycles, such as when the SCN is experimentally ablated or an animal is in conditions of constant darkness, daylight no longer acts as a zeitgeber and circadian organization gradually becomes out of sync with the environment (i.e., free running rhythms persist). However, under certain conditions, another powerful zeitgeber- food- can restore, synchronize, and propagate circadian rhythmicity (Boulos and Terman, 1980; Stephan, 2002).
The process whereby food/mealtime acts as the stimulus for synchronizing the circadian system is referred to as “food entrainment”. There is strong evidence that an SCN-independent “food-entrainable” oscillator exists, possessing the canonical properties of a circadian clock, although its location has not yet been identified (Boulos and Terman, 1980; Mistlberger, 1994, 2009; Stephan, 2002; Patton and Mistlberger, 2013).
If food is restricted to one or two daily mealtimes, then within a few days rodents begin to show food anticipatory activity (FAA), which is a higher level of activity (e.g., wheel running or exploration of their home cage) during the few hours leading up to the daily meal (Boulos and Terman, 1980; Mistlberger, 1994; Stephan, 2002). FAA is thought to represent food seeking behavior. Scheduled feeding can entrain the entire circadian system under conditions of constant darkness, or can dissociate peripheral rhythms from the central SCN-driven rhythms under normal conditions with a dominate light-dark cycle (Damiola et al., 2000).
It is not yet known what the specific mechanism is by which mealtime exerts its entraining effect on the circadian system. There may be multiple food-related stimuli that are capable as functioning as zeitgebers, entraining both central and peripheral oscillators. For example, metabolic hormones (e.g., ghrelin, corticosterone, leptin, insulin, and glucagon) exhibit daily rhythms of synthesis and secretion that are synchronized by meal time (Patton and Mistlberger, 2013). These hormones may act as signals by which oscillators in peripheral organs are coupled to daily mealtime (Dibner et al., 2010).
Importantly, because particular feeding schedules can shift the timing of clock genes and rhythms in peripheral organs, dissociating peripheral oscillators from the SCN, it suggests that feeding behavior could be the mediating factor by which SCN coordinates peripheral physiological rhythms (Figure 1; Boulos and Terman, 1980; Damiola et al., 2000; Dibner et al., 2010). In other words, feeding behavior may keep central and peripheral rhythms coupled together.
Although the specific mechanism by which food/mealtime exert the powerful synchronizing effects on peripheral rhythms, remains unknown, once it is identified, targeted interventions to help synchronize circadian rhythms can be developed. Synchronizing rhythms may be beneficial for preventing or delaying age-related conditions if rhythms become uncoupled.
Harmful Effects of Disrupted Circadian Rhythms
The importance of keeping the circadian system synchronized is illustrated by the harmful outcomes of disrupted rhythms. It is well reported that circadian dysfunction can have dramatic effects on health in both animal models and humans. Disturbances in the circadian system can have negative effects on cognition, immune functioning, metabolic processes, and the cardiovascular system, resulting in fatigue, disorientation, insomnia, altered hormone profiles, higher morbidity, and higher mortality in humans and animal models (Penev et al., 1998; Fu et al., 2002; Filipski et al., 2003; Davis and Mirick, 2006; Fujino et al., 2006; Kubo et al., 2006; Coogan and Wyse, 2008; Anea et al., 2009; Gibson et al., 2009; Gery and Koeffler, 2010; Jung-Hynes et al., 2010; Coogan et al., 2013).
In humans, the experience of jet-lag or shift work represents a state when the circadian system is out of sync with the environment, and is associated with damaging effects on health. Shift-workers are at a higher risk of harmful conditions such as metabolic syndrome, obesity, cancer, and diabetes, which may partly result from the disrupted rhythmicity of meals and sleep (Bass and Takahashi, 2010).
In animals, disrupted circadian rhythms also result in suboptimal health (Filipski et al., 2003; Anea et al., 2009; Wang et al., 2010). For example, in aged mice, phase shifting (analogous to jetlag) is associated with higher mortality (Davidson et al., 2006). Similarly, continuous reversal of the light-dark cycle, decreases survival in cardiomyopathic hamsters (Penev et al., 1998).
What jet-lag, shift work, and phase shifting have in common, is that underlying rhythms become uncoupled and out of sync. Uncoupling metabolic process from circadian drives may reduce efficiency and cause imbalances in physiological activities. A similar process may underlie age-related changes and contribute to neurodegenerative disease.
Circadian Rhythms and Neurodegenerative Disease
It is well documented that circadian rhythms become disorganized and lose amplitude during healthy aging and neurodegenerative disease (Witting et al., 1994; Hofman and Swaab, 2006; Kondratova and Kondratov, 2012). In rodent models, there are age-related changes in the rhythms of parameters such as body temperature, activity-wakefulness, locomotor activity, and drinking behavior (Weinart, 2000; Kolker et al., 2003). Aged animals given fetal SCN implants have increased longevity, suggesting that age-related impairments may be due to changes in the SCN (Hurd and Ralph, 1998).
In humans, similar age-related changes in melatonin secretion, body temperature rhythms, and sleep-wake cycles are also experienced (Duffy et al., 2002; Yoon et al., 2003; Hofman and Swaab, 2006). These circadian disruptions are particularly common in patients with AD, who often complain of disrupted sleep patterns as well as agitation, restlessness, wandering, and verbal outbursts during the late afternoon or early evening, referred to as “sundowning” and occurs in an estimated 13–66% of AD patients (Volicer et al., 2001). Along with these behavioral symtpoms, dementia patients also show disordered melatonin rhythms (Mishima et al., 1999).
Importantly, the results of a large prospective study suggested that the age-related changes in circadian activity patterns, predicted subsequent AD or mild cognitive impairment (Tranah et al., 2011). Thus, impaired rhythms may be a preclinical biomarker of disease.
Monitoring skin temperature is useful for assessing circadian rhythmicity at the gross level. One study showed that proximal skin temperature but not distal skin temperature was higher during the day in AD patients compared with healthy elderly subjects (Most et al., 2012). Higher proximal skin temperature was associated with daytime sleepiness, which could exacerbate cognitive symptoms.
Actigraphy, a noninvasive method for monitoring rest/activity cycles, is another technique for evaluating rhythmicity in AD patients (Witting et al., 1990; Satlin et al., 1992; van Someren et al., 1996; Ancoli-Israel et al., 2003a; Hatfield et al., 2004). Daily activity-rest rhythms of demented patients exhibit increased fragmentation, a loss of amplitude, and higher nighttime activity (van Someren et al., 1996; Hatfield et al., 2004). These rest-activity disturbances may be correlated with the severity of dementia (Witting et al., 1990). AD patients also show reduced scale invariance of activity fluctuations (Hu et al., 2009). This parameter is found to be dependent upon the SCN in rodents (Hu et al., 2007), suggesting that the changes in scale-invariant locomotor patterns in AD patients may reflect SCN dysfunction.
Post mortem studies have revealed neuropathological changes in the SCN of healthy elderly and AD patients (reviewed by Hofman and Swaab, 2006). Although there have been some inconsistencies, possible pathological changes in the SCN of AD patients include decreased vasopressin-, neurotensin- and melatonin-expressing neurons, increased astrocyte to neuron ratio, neuronal loss in the SCN, and an overall decrease in SCN volume (Swaab et al., 1985; Stopa et al., 1999; Liu et al., 2000; Wu et al., 2007; Harper et al., 2008). Neurodegeneration of SCN in AD patients is correlated with the magnitude of circadian rhythm impairment in core body temperature (Harper et al., 2008).
AD patients also show desynchrony in rhythmic expression of circadian clock genes in the oscillation between cingulate cortex, pineal gland and the bed nucleus of the stria terminalis (BNST; Cermakian et al., 2011), suggesting that the circadian oscillators outside the SCN become uncoupled in AD patients. Hatfield et al. (2004) came to a similar conclusion when they compared activity/rest and cortisol rhythms in AD patients and concluded that the loss of circadian control of rest/activity was not a result of a global circadian disruption.
There are a few potential pathways by which circadian rhythms could be affected in AD (for a review see Coogan et al., 2013). The input from photic and non-photic zeitgebers may become weakened due to age-related changes in physiology and behavior. For example, with increasing age people often experience changes in eye functioning and have routines with less physical exercise, both of which could reduce input into the circadian system. Older age and retirement often result in more sporadic scheduling of activities such as mealtime, which can play an important role in synchronizing central and peripheral rhythms in animal models. The reduced input from these changes in physiology and behavior may then be compounded by changes in SCN and weakened internal feedback mechanisms within the body. If the resulting SCN output is weak, then pineal activity, hippocampal functioning, and the HPA axis are affected.
Given the considerable evidence of circadian dysfunction in AD patients, chronotherapeutics targeting circadian abnormalities have been used in attempts to reset the clock (Coogan et al., 2013). The most marked circadian abnormality in AD patients is reduced amplitude of rhythms and rhythm fragmentation, suggesting that interventions should be aimed at strengthening zeitgebers instead of phase-resetting. Changes to the patient’s environment (e.g., light therapy), behavioral routines (e.g., exercise), and circulating hormone levels (e.g., melatonin supplementation), have all been attempted to strengthen rhythmicity.
Evening and/or morning light therapy have been shown to help stabilize rhythms and improve sleep (Satlin et al., 1992; Mishima et al., 1994; Yamadera et al., 2000; Ancoli-Israel et al., 2003b). One study found that in institutionalized patients, light therapy was only minimally beneficial at stabilizing circadian phase, but was more beneficial when combined with melatonin treatment (Dowling et al., 2008). A double-blind study showed that melatonin treatment improved cognition, decreased nocturnal activity, and increased nocturnal sleep in AD patients (Asayama et al., 2003), although larger follow-up studies have showed no benefits of melatonin treatment (Singer et al., 2003; Gehrman et al., 2009).
Along with promoting health, regulating circadian rhythmicity may also affect wellbeing. Elderly demented women with higher daytime activity levels and lower nocturnal activity (i.e., consolidated, nonfragmented sleep/wake cycles) showed higher levels of wellbeing compared to elderly women with more disrupted sleep-patterns (Carvalho-Bos et al., 2007).
Given the difficulty of assessing core circadian processes in patients, animal models are useful for elucidating circadian alterations. Rats injected with transgenic cells overexpressing β/A4 amyloid into the SCN, displayed disrupted locomotor rhythms indicative of deterioration of circadian regulation (Tate et al., 1992). Similarly, hamsters injected with β-amyloid 25–35 into the SCN, showed phase-advanced and less consistent diurnal activity rhythms (Furio et al., 2002). These effects were attenuated by melatonin administration.
Some transgenic mouse models of AD such as APP23, Tg2576, and 3xTg display disturbances in circadian activity rhythms (Van Dam et al., 2003; Vloeberghs et al., 2004; Sterniczuk et al., 2010). The 3xTg AD mouse model shows abnormalities in circadian rhythmicity that precede AD pathology (Sterniczuk et al., 2010). In contrast, no circadian abnormalities in sleep-wake behavior were reported in the AβPPswe/PSEN1A246E or SPPswe/PS1dE9 transgenic mouse of AD (Jyoti et al., 2010; Otalora et al., 2012).
To summarize, disrupted circadian rhythms are associated with higher morbidity and higher mortality in humans and animal models. With increasing age, rhythmicity becomes more irregular and these changes are more extreme for AD patients and may precede the cognitive impairment associated with AD. Light therapy has had some success at regulating circadian rhythmicity and improving symptoms in AD patients.
Uncoupled Hypothesis: Using Food-Entrainment to Synchronize Rhythms
It is largely assumed that the circadian disruptions associated with age and neurodegenerative diseases, such as AD, are caused from the dampening of central SCN-driven rhythms. However, another possibility is that the disrupted patterns in behavior and physiological rhythms are due to the central rhythms becoming uncoupled from and out of sync with peripheral rhythms, and not from disruptions in central clock functioning.
Chen et al. (2014) used a transgenic Drosophila model, to provide the first evidence that progressive circadian deficits analogous to those experienced by AD patients were not due to an arrhythmic internal timekeeping mechanism, but rather due to a disruption in the communication between a central timekeeping mechanism and peripheral rhythms. The Aβ expression in the Drosophila model resulted in age-related disturbances in circadian rhythms, causing sporadic sleep-wake behaviors. Despite the behavioral irregularities, the central timekeeping mechanism of this Drosophila model appeared intact. The behavioral arrhythmia was not due to a failing central clock.
If these findings translate to AD patients, then it would suggest that the SCN would stay entrained to daylight while the peripheral rhythms affecting behavior become out of sync. If circadian behavioral abnormalities in patients are not caused by a loss of SCN function, then it could have potential implications for the treatment and prevention of AD.
For example, if in AD patients, the SCN is intact but central and peripheral rhythms become uncoupled, then, because feeding plays a dominate role in synchronizing central and peripheral rhythms, it may be possible to draw on the food-entrainment literature for insights into how we can bring physiological processes back in sync.
Maywood et al. (2010) used a food-entrainment paradigm to restore circadian disturbances in behavior and peripheral metabolic processes in the R6/2 mouse model of Huntington’s disease. This demonstrates that it is possible to regularize circadian behavioral and metabolic disturbances using food-entrainment in a mouse model of neurodegenerative disease.
Food-entrainment paradigms would be challenging to introduce as therapies for human patients, but there may be a way to pharmacologically induce synchrony between central and peripheral rhythms using a feeding-related peptide such as ghrelin.
Ghrelin: Circadian System
The metabolic hormone, ghrelin, may be one promising candidate signal that could be particularly useful for synchronizing rhythms and preventing age-related memory loss in AD.
Ghrelin is an orexigenic hormone synthesized by oxyntic cells in the stomach and by neurons in the medial and lateral hypothalamic nuclei (Kojima et al., 1999; Cowley et al., 2003). It is a peripheral and central hormone directly implicated in feeding related activity, and an endogenous ligand for the growth hormone secratague receptor (GHS-R1a; Kojima et al., 1999).
Ghrelin acts in the pituitary and hypothalamus to stimulate growth hormone secretion, energy homeostasis, appetite, wakefulness, weight gain, and adrenocorticotropic hormone and cortisol release (Kojima et al., 1999; Wren et al., 2000; Tschöp et al., 2000; Kojima and Kangawa, 2005; Szentirmai et al., 2006; Chen et al., 2009; Castañeda et al., 2010). Ghrelin stimulates feeding (Nakazato et al., 2001; Toshinai et al., 2006), and circulating levels rise prior to mealtime in both rodents (Bodosi et al., 2004; Drazen et al., 2006; LeSauter et al., 2009) and humans (Cummings et al., 2001; Frecka and Mattes, 2008).
In addition to regulating appetite, there is evidence that ghrelin also plays a role in the circadian system by directly entraining circadian clocks that drive behavior or indirectly by stimulating appetite and activity. Ghrelin positive immunoreactive neurons are found in brain regions involved for circadian timing such as the paraventricular, dorsomedial, ventromedial, and arcuate nuclei, and may affect SCN processes via the ventromedial arcuate nucleus (Cowley et al., 2003; Yi et al., 2006). Under restricted feeding conditions, the circadian system is sensitive to ghrelin and other feeding-related neuropeptides (Yannielli et al., 2007). Additionally, peripherally administered ghrelin has been shown to modulate SCN activity in rats and mice and attenuate light-induced phase delay in mice (Yi et al., 2008).
However, there is mixed evidence as to whether ghrelin can act a zeitgeber. Two studies show that ghrelin receptor knock out mice fail to anticipate a daily meal (LeSauter et al., 2009; Davis et al., 2011; Verhagen et al., 2011), however other studies have shown that ghrelin ligand or receptor knock-out mice do continue to show FAA (Blum et al., 2009; Szentirmai et al., 2010; Gunapala et al., 2011).
Overall, the evidence suggests that ghrelin is not the unidentified “food-entrainable oscillator” but rather that it exerts effects on the circadian system by acting downstream from or in parallel with a food entrainable oscillator (Patton and Mistlberger, 2013). Even though ghrelin may not be necessary for anticipatory activity it may still promote its expression by strengthening the zeitgeber.
Another useful paradigm for studying food-entrainment, which may be more translatable to humans, is examining the effects of a daily palatable snack or meal on the circadian system of animals that are not food-restricted. Without caloric restriction, a palatable snack (e.g., chocolate) can engender food anticipatory behavior (Mistlberger and Rusak, 1987; Mendoza et al., 2005; Hsu et al., 2010).
Ghrelin has been examined as a modulator factor in palatable meal anticipation with mixed results. One study found that plasma ghrelin levels correlated with locomotor activity counts during the 3 h prior to the chocolate snack, and that injected ghrelin increased anticipatory activity (Merkestein et al., 2012). However, another study found no increase in ghrelin prior to a daily chocolate snack (Dailey et al., 2012).
Overall, evidence suggests that ghrelin could be involved in the mechanism by which mealtime acts as a zeitgeber. However, there is not enough evidence to draw conclusions about whether ghrelin could be useful for synchronizing central and peripheral rhythms in the elderly at risk for AD. It remains an empirical question whether appropriately timed daily administration of ghrelin could help to amplify food-entrainment to daily scheduled meals in the elderly. If the uncoupling of rhythms contributes to age-related neurodegenerative disease, then combining ghrelin treatment with scheduled mealtimes may help synchronize rhythms. It is possible that bringing out-of-sync rhythms back in sync could promote healthy aging, delay the onset of neurodegenerative disease, and may even help reduce symptoms and improve wellbeing.
Ghrelin: Memory and Alzheimer’s Disease
Although the potential of ghrelin to entrain the circadian system of elderly at risk for AD remains to be confirmed, recent evidence suggests that administering ghrelin may have other potential benefits as well. Extra-hypothalamic actions of ghrelin have been identified, including pro- cognitive, antidepressant, (anti-)anxiogenic, and neuroprotective properties (Asakawa et al., 2001; Kanehisa et al., 2006; Lutter et al., 2008; Andrews, 2011; Frago et al., 2011; Steiger et al., 2011). Consistently, intracranial infusions and systemic ghrelin treatments have beneficial mnemonic effects (Carlini et al., 2002, 2004, 2007, 2008, 2010a,b; Diano et al., 2006; Atcha et al., 2009; Tóth et al., 2010; Chen et al., 2011; Chen, 2012), affect measures of hippocampal synaptic plasticity (Diano et al., 2006; Carlini et al., 2010b; Chen et al., 2011), and promote hippocampal neurogenesis (Moon et al., 2009; Chen, 2012).
Carlini et al. (2002) were the first to demonstrate that ghrelin treatment can improve memory retention. The researchers injected the peptide intracerebroventricularly (ICV) in rats and found that the treatment improved memory in a dose-dependent manner, as measured by latency time in a step-down behavioral test. Since that study, the beneficial mnemonic effects of intracranial infusions or systemic ghrelin treatment have been repeatedly replicated (Carlini et al., 2004, 2007, 2008, 2010a,b; Diano et al., 2006; Atcha et al., 2009; Tóth et al., 2010; Chen et al., 2011; Chen, 2012).
Importantly, beyond its effects on the circadian system and hippocampal dependent memory, ghrelin may also have potential for preventing or treating neurodegenerative disease.
Neurodegenerative disorders often display coexisting metabolic dysfunction, and there are several converging lines of evidence linking metabolic syndromes with an increased risk of developing AD (Naderali et al., 2009; Kapogiannis and Mattson, 2011; Cai et al., 2012). For example, there is a growing literature suggesting that insulin deficiency and insulin resistance act as mediators of AD-type neurodegeneration. This has led some to refer to AD as “type 3 diabetes”, a form of diabetes that selectively involves the brain (Steen et al., 2005; de la Monet and Wands, 2008). Because ghrelin has been shown to modulate insulin sensitivity (Chen et al., 2010), as well as several other metabolic and mnemonic effects, ghrelin may be a potential candidate molecule responsible for the relationship between metabolic and cognitive dysfunction. It is possible that disruption of the normal modulation of ghrelin secretion may contribute to the metabolic changes associated with AD.
Indeed, there is increasing evidence suggesting an association between ghrelin and AD pathology (Gahete et al., 2011). The first line of evidence is that involuntary weight loss and nutritional deficiencies are common in individuals diagnosed with AD, as well as being associated with cognitive impairment in non-demented elderly (Inelmen et al., 2009; Theodoropoulou et al., 2012).
Importantly, weight loss may precede the memory loss associated with dementia (Buchman et al., 2005; Stewart et al., 2005; Johnson et al., 2006; Knopman et al., 2007). Because ghrelin is an important regulator of appetite, the age-related weight loss is in agreement with the finding of an age-related decline of plasma ghrelin concentrations as well as the age-related decline in growth-hormone releasing effect of ghrelin (Figure 2; Rigamonti et al., 2002; Broglio et al., 2003). AD patients compared with age-matched controls, also show a reduction in local ghrelin production in the brain (Gahete et al., 2010). Because weight loss appears to precede cognitive impairment in patients with AD (Knopman et al., 2007), metabolic changes could be targets for early detection and prevention of cognitive decline.
Figure 2. Hypothesized link between ghrelin and symptoms often associated with aging and Alzheimer’s disease. Ghrelin has been shown to directly affect hippocampal plasticity and neurogenesis, hunger-levels, and circadian processes. Both aging and Alzheimer’s disease (AD) are associated with lower levels of circulating ghrelin. Low ghrelin levels may result in reduced hippocampal plasticity and neurogenesis, and contribute to the cognitive deficits associated with old-age and AD. Lower circulating levels of ghrelin may also reduce hunger levels, and may partially underlie the weight loss associated with older age and AD. Finally, if ghrelin acts to enhance feeding-related zeitgebers, then reductions in circulating ghrelin could dampen food-entrained oscillators and disrupt circadian rhythmicity.
Although the human data examining the relationship between ghrelin and AD pathology is promising, there have been some mixed results. For example, one study reported that ghrelin levels do not vary in the cerebrospinal fluid of AD patients compared with age-matched controls (Proto et al., 2006) and another reported that ghrelin levels were negatively correlated with several cognitive domains, including verbal memory and working memory (Spitznagel et al., 2010).
The second line of evidence in support of a role of ghrelin in the development of AD comes from animal models. The first demonstration of a direct effect of ghrelin on AD-like alterations was in an AD mouse model (SAMP8), which develops an age-related increase in β-amyloid. In this model, ghrelin treatment improved retention on the T-maze foot shock avoidance task (Diano et al., 2006). Another mouse model, generated by intrahippocampal injection of oligometric forms of the Aβ peptide, demonstrated that systemic injection of ghrelin rescued performance on two behavioral paradigms (Y-maze and passive avoidance tasks), as well as attenuated AD-associated neuropathological abnormalities, possibly by inhibiting microgliosis and protecting neuronal integrity (Moon et al., 2014). Furthermore, neurons treated with ghrelin for 1 h show decreased tau hyperphosphorylation (Chen et al., 2010).
Although the evidence from human patients and from animal models is minimal and mixed, it is possible that an age-related decline in ghrelin may contribute to disruptions in age-related circadian disruption, weight loss, cognitive decline, and reductions in hippocampal neurogenesis (Figure 2). Because of this, well-timed supplements of ghrelin may have potential benefits for synchronizing an uncoupled circadian system, promoting hippocampal plasticity and neurogenesis, benefitting memory, and improving appetite and thus possibly nutrition, and may even help reduce pathology in AD patients.
Much more research needs to be done before drawing any conclusions, but taking a systems level approach that considers overall health hints at a potentially powerful role of ghrelin.
It has been over a 100 years since AD was first identified by German psychiatrist and neuropathologist Aloysius Alzheimer, and yet we remain without effective treatments or a cure for this devastating disease. AD and other dementias are arguably the greatest global public health challenge of the 21st century. It is imperative that research go towards understanding the underlying disease processes at every level of analysis from genetics and molecular processes to systems and behavior; however, here it was proposed that there is great potential for identifying inexpensive and effective interventions by studying AD from a systems level approach that considers synchrony in the circadian system.
Aging is the greatest risk factor for developing AD. If we think about AD and other age-related neurodegenerative diseases as taking 60–70 years to develop, then it seems reasonable to think that there are ways to slow the development even further. Cell structures within tissues maintain a continuous synthesis and degradation of worn-out proteins that is integral to normal function. This process slows during aging, and the oxidative damage to proteins and protein misfolding lead to the accumulation of altered and abnormal proteins, which may contribute to neurodegenerative disease (Martinez-Vicente et al., 2005; Martinez-Vicente and Cuervo, 2007; Rattan, 2010). By promoting overall health, we may be able to maintain our natural defenses and cellular health.
Studying circadian rhythm disruption in AD holds great promise for inexpensive interventions. We know that harmonious interaction of internal and environmental rhythms ensures that physiological processes occur at an optimal time, and that maintaining this synchrony is best for longevity. If uncoupled circadian rhythms exacerbate symptoms or contribute to disease progression, then we may be able to draw from the food-entrainment literature to identify ways to synchronize peripheral rhythms with the SCN in elderly at risk for AD.
Future research should look for the earliest cues that internal rhythms are becoming uncoupled. A combination of light therapy, scheduled mealtimes, and other interventions, such as appropriately timed ghrelin administration, may have the potential to maintain circadian organization and synchrony throughout the body, and slow down the progression of disease. Delaying the onset of symptoms can potentially reduce the impact these devastating diseases have on the patients, their families, and society.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This research was funded by a Gates-Cambridge fellowship to Brianne A. Kent. The author would like to thank Professor Ralph Mistlberger, Professor Christopher Dobson, and Dr. Glenn Landry for helpful discussions while preparing the review.
Ancoli-Israel, S., Gehrman, P., Martin, J. L., Shochat, T., Marler, M., Corey-Bloom, J., et al. (2003b). Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer’s disease patients. Behav. Sleep Med. 1, 22–36. doi: 10.1207/s15402010bsm0101_4
Anea, C. B., Zhang, M., Stepp, D. W., Simkins, G. B., Reed, G., Fulton, D. J., et al. (2009). Vascular disease in mice with a dysfunctional circadian clock. Circulation 119, 1510–1517. doi: 10.1161/CIRCULATIONAHA.108.827477
Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fujimaya, M., et al. (2001). A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 74, 143–147. doi: 10.1159/000054680
Asayama, K., Yamadera, H., Ito, T., Suzuki, H., Kudo, Y., and Endo, S. (2003). Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon Med. Sch. 70, 334–341. doi: 10.1272/jnms.70.334
Atcha, Z., Chen, W.-S., Ong, A. B., Wong, F.-K., Neo, A., Browne, E. R., et al. (2009). Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology (Berl) 206, 415–427. doi: 10.1007/s00213-009-1620-6
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804. doi: 10.1056/NEJMoa1202753
Bianchetti, A., Scuratti, A., Zanetti, O., Binetti, G., Frisoni, G. B., Magni, E., et al. (1995). Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia 6, 108–112. doi: 10.1159/000106930
Blum, I. D., Patterson, Z., Khazall, R., Lamont, E. W., Sleeman, M. W., Horvath, T. L., et al. (2009). Reduced anticipatory locomotor responses to scheduled meals in ghrelin receptor deficient mice. Neuroscience 164, 351–359. doi: 10.1016/j.neuroscience.2009.08.009
Bodosi, B., Gardi, J., Hajdu, I., Szentirmai, E., Obal, F. Jr., and Krueger, J. M. (2004). Rhythms of ghrelin, leptin and sleep in rats: effects of the normal diurnal cycle, restricted feeding and sleep deprivation. J. Physiol. Regul. Integr. Comp. Physiol. 287, R1071–R1079. doi: 10.1152/ajpregu.00294.2004
Broglio, F., Benso, A., Castiglioni, C., Gottero, C., Prodam, F., Destefanis, S., et al. (2003). The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J. Clin. Endocrinol. Metab. 88, 1537–1542. doi: 10.1210/jc.2002-021504
Buchman, A. S., Wilson, R. S., Bienias, J. L., Shah, R. C., Evans, D. A., and Bennett, D. A. (2005). Change in body mass index and risk of incident Alzheimer disease. Neurology 65, 892–897. doi: 10.1212/01.wnl.0000176061.33817.90
Cai, H., Cong, W. N., Ji, S., Rothman, S., Maudsley, S., and Martin, B. (2012). Metabolic dysfunction in Alzheimer’s disease and related neurodegenerative disorders. Curr. Alzheimer Res. 9, 5–17. doi: 10.2174/156720512799015064
Carlini, V. P., Gaydou, R. C., Schiöth, H. B., and de Barioglio, S. R. (2007). Selective serotonin reuptake inhibitor (fluoxetine) decreases the effects of ghrelin on memory retention and food intake. Regul. Pept. 140, 65–73. doi: 10.1016/j.regpep.2006.11.012
Carlini, V. P., Ghersi, M., Schiöth, H. B., and de Barioglio, S. R. (2010a). Ghrelin and memory: differential effects on acquisition and retrieval. Peptides 31, 1190–1193. doi: 10.1016/j.peptides.2010.02.021
Carlini, V. P., Martini, A. C., Schiöth, H. B., Ruiz, R. D., Fiol de Cuneo, M., and de Barioglio, S. R. (2008). Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 153, 929–934. doi: 10.1016/j.neuroscience.2008.03.015
Carlini, V. P., Monzón, M. E., Varas, M. M., Cragnolini, A. B., Schiöth, H. B., Scimonelli, T. N., et al. (2002). Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem. Biophys. Res. Commun. 299, 739–743. doi: 10.1016/s0006-291x(02)02740-7
Carlini, V. P., Perez, M. F., Salde, E., Schiöth, H. B., Ramirez, O. A., and de Barioglio, S. R. (2010b). Ghrelin induced memory facilitation implicates nitric oxide synthase activation and decrease in the threshold to promote LTP in hippocampal dentate gyrus. Physiol. Behav. 101, 117–123. doi: 10.1016/j.physbeh.2010.04.026
Carlini, V. P., Varas, M. M., Cragnolini, A. B., Schiöth, H. B., Scimonelli, T. N., and de Barioglio, S. R. (2004). Differential role of the hippocampus, amygdala and dorsal raphe nucleus in regulating feeding, memory and anxiety-like behavioral responses to ghrelin. Biochem. Biophys. Res. Commun. 313, 635–641. doi: 10.1016/j.bbrc.2003.11.150
Carvalho-Bos, S. S., Riemersma-van der Lek, R. F., Waterhouse, J., Reilly, T., and van Someren, E. J. W. (2007). Strong association of the rest-activity rhythm with well-being in demented elderly women. J. Geriatr. Psychiatry 15, 92–100. doi: 10.1097/01.JGP.0000236584.03432.dc
Castañeda, T. R., Tong, J., Datta, R., Culler, M., and Tschöp, M. H. (2010). Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 31, 44–60. doi: 10.1016/j.yfrne.2009.10.008
Cermakian, N., Waddington Lamont, E., Boudreau, P., and Boivin, D. B. (2011). Circadian clock gene expression in brain regions of Alzheimer’s disease patients and control subjects. J. Biol. Rhythms 26, 160–170. doi: 10.1177/0748730410395732
Chen, C. Y., Asakawa, A., Fujimiya, M., Lee, S. D., and Inui, A. (2009). Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol. Rev. 61, 430–481. doi: 10.1124/pr.109.001958
Chen, Y., Cao, C.-P., Li, C.-R., Wang, W., Zhang, D., Han, L.-L., et al. (2010). Ghrelin modulates insulin sensitivity and tau phosphorylation in high glucose-induced hippocampal neurons. Biol. Pharm. Bull. 33, 1165–1169. doi: 10.1248/bpb.33.1165
Chen, K. F., Possidente, B., Lomas, D. A., and Crowther, D. C. (2014). The central molecular clock is robust in the face of behavioural arrhythmia in a Drosophila model of Alzheimer’s disease. Dis. Model Mech. 7, 445–458. doi: 10.1242/dmm.014134
Chen, L., Xing, T., Wang, M., Miao, Y., Tang, M., Chen, J., et al. (2011). Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur. J. Neurosci. 33, 266–275. doi: 10.1111/j.1460-9568.2010.07491.x
Coogan, A. N., Schutová, B., Husung, S., Furczyk, K., Baune, B. T., Kropp, P., et al. (2013). The circadian system in Alzheimer’s disease: disturbances, mechanisms and opportunities. Biol. Psychiatry 74, 333–339. doi: 10.1016/j.biopsych.2012.11.021
Cowley, M. A., Smith, R. G., Diano, S., Tschöp, M., Pronchuk, N., Grove, K. L., et al. (2003). The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37, 649–661. doi: 10.1016/s0896-6273(03)00063-1
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., and Weigle, D. S. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714–1719. doi: 10.2337/diabetes.50.8.1714
Damiola, F., Le Minh, N., Preitner, N., Kornmann, B., Fleury-Olela, F., and Schibler, U. (2000). Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes. Dev. 14, 2950–2961. doi: 10.1101/gad.183500
Davidson, A. J., Sellix, M. T., Daniel, J., Yamazaki, S., Menaker, M., and Block, G. D. (2006). Chronic jet-lag increases mortality in aged mice. Curr. Biol. 16, R914–R916. doi: 10.1016/j.cub.2006.09.058
Davis, J. F., Choi, D. L., Clegg, D. J., and Benoit, S. C. (2011). Signaling through the ghrelin receptor modulates hippocampal function and meal anticipation in mice. Physiol. Behav. 103, 39–43. doi: 10.1016/j.physbeh.2010.10.017
Davis, S., and Mirick, D. K. (2006). Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in seattle. Cancer Causes Control 17, 539–545. doi: 10.1007/s10552-005-9010-9
Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., et al. (2006). Ghrelin controls hippocampal spine synapse density and memory performance. Nat. Neurosci. 9, 381–388. doi: 10.1038/nn1656
Dibner, C., Schibler, U., and Albrecht, U. (2010). The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 72, 517–549. doi: 10.1146/annurev-physiol-021909-135821
Dowling, G. A., Burr, R. L., van Someren, E. J. W., Hubbard, E. M., Luxenberg, J. S., Mastick, J., et al. (2008). Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease. J. Am. Geriatr. Soc. 56, 239–246. doi: 10.1111/j.1532-5415.2007.01543.x
Drazen, D. L., Vahl, T. P., D’Alessio, D. A., Seeley, R. J., and Woods, S. C. (2006). Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 147, 23–30. doi: 10.1210/en.2005-0973
Duffy, J. F., Zeitzer, J. M., Rimmer, D. W., Klerman, E. B., Dijk, D.-J., and Czeisler, C. A. (2002). Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. J. Physiol. Endocrinol. Metab. 282, E297–E303. doi: 10.1152/ajpendo.00268.2001
Filipski, E., King, V. M., Li, X., Granda, T. G., Mormont, M.-C., Claustrat, B., et al. (2003). Disruption of circadian coordination accelerates malignant growth in mice. Pathol. Biol. (Paris) 51, 216–219. doi: 10.1016/s0369-8114(03)00034-8
Fu, L., Pelicano, H., Liu, J., Huang, P., and Lee, C. C. (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111, 41–50. doi: 10.1016/s0092-8674(02)01223-0
Fujino, Y., Iso, H., Tamakoshi, A., Inaba, Y., Koizumi, A., Kubo, T., et al. (2006). A prospective cohort study of shift work and risk of ischemic heart disease in Japanese male workers. J. Epidemiol. 164, 128–135. doi: 10.1093/aje/kwj185
Furio, A. M., Cutrera, R. A., Thea, V. C., Lloret, S. P., Riccio, P., Caccuri, R. L., et al. (2002). Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25–35 in the suprachiasmatic nuclei. Cell. Mol. Neurobiol. 22, 699–709. doi: 10.1023/A:1021805023906
Gahete, M. D., Córdoba-Chacón, J., Kineman, R. D., Luque, R. M., and Castaño, J. P. (2011). Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer’s disease. Peptides 32, 2225–2228. doi: 10.1016/j.peptides.2011.09.019
Gahete, M. D., Rubio, A., Córdoba-Chacón, J., Gracia-Navarro, F., Kineman, R. D., Avila, J., et al. (2010). Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer’s disease patients. J. Alzheimers Dis. 22, 819–828. doi: 10.3233/JAD-2010-100873
Gandy, S., and DeKosky, S. T. (2013). Toward the treatment and prevention of Alzheimer’s disease: rational strategies and recent progress. Annu. Rev. Med. 64, 367–383. doi: 10.1146/annurev-med-092611-084441
Gehrman, P. R., Connor, D. J., Martin, J. L., Shochat, T., Corey-Bloom, J., and Ancoli-Israel, S. (2009). Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. J. Geriatr. Psychiatry 17, 166–169. doi: 10.1097/JGP.0b013e318187de18
Gibson, E. M., Williams, W. P., and Kriegsfeld, L. J. (2009). Aging in the circadian system: considerations for health, disease prevention and longevity. Exp. Gerontol. 44, 51–56. doi: 10.1016/j.exger.2008.05.007
Guilding, C., and Piggins, H. D. (2007). Challenging the omnipotence of the suprachiasmatic timekeeper: are circadian oscillators present throughout the mammalian brain? Eur. J. Neurosci. 25, 3195–3216. doi: 10.1111/j.1460-9568.2007.05581.x
Gunapala, K. M., Gallardo, C. M., Hsu, C. T., and Steele, A. D. (2011). Single gene deletions of orexin, leptin, neuropeptide Y and ghrelin do not appreciably alter food anticipatory activity in mice. PLoS One 6:e18377. doi: 10.1371/journal.pone.0018377
Harper, D. G., Stopa, E. G., Kuo-Leblanc, V., McKee, A. C., Asayama, K., Volicer, L., et al. (2008). Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. Brain 131, 1609–1617. doi: 10.1093/brain/awn049
Hatfield, C. F., Herbert, J., van Someren, E. J., Hodges, J. R., and Hastings, M. H. (2004). Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer’s dementia. Brain 127, 1061–1074. doi: 10.1093/brain/awh129
Hu, K., Scheer, F. A. J. L., Ivanov, P. C., Buijs, R. M., and Shea, S. A. (2007). The suprachiasmatic nucleus functions beyond circadian rhythm generation. Neuroscience 149, 508–517. doi: 10.1016/j.neuroscience.2007.03.058
Hu, K., van Someren, E. J. W., Shea, S. A., and Scheer, F. A. J. L. (2009). Reduction of scale invariance of activity fluctuations with aging and Alzheimer’s disease: involvement of the circadian pacemaker. Proc. Natl. Acad. Sci. U S A 106, 2490–2494. doi: 10.1073/pnas.0806087106
Inelmen, E. M., Sergi, G., Coin, A., Girardi, A., and Manzato, E. (2009). An open-ended question: Alzheimer’s disease and involuntary weight loss: which comes first? Aging Clin. Exp. Res. 22, 192–197. doi: 10.3275/6677
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216. doi: 10.1016/S1474-4422(12)70291-0
Jung-Hynes, B., Reiter, R. J., and Ahmad, N. (2010). Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J. Pineal Res. 48, 9–19. doi: 10.1111/j.1600-079x.2009.00729.x
Jyoti, A., Plano, A., Riedel, G., and Platt, B. (2010). EEG, activity and sleep architecture in a transgenic AβPPswe/PSEN1A246E Alzheimer’s disease mouse. J. Alzheimers Dis. 22, 873–887. doi: 10.3233/JAD-2010-100879
Kalsbeek, A., Palm, I. F., La Fleur, S. E., Scheer, F. A. J. L., Perreau-Lenz, S., Ruiter, M., et al. (2006). SCN outputs and the hypothalamic balance of life. J. Biol. Rhythms 21, 458–469. doi: 10.1177/0748730406293854
Kanehisa, M., Akiyoshi, J., Kitaichi, T., Matsushita, H., Tanaka, E., Kodama, K., et al. (2006). Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1403–1407. doi: 10.1016/j.pnpbp.2006.05.005
Kapogiannis, D., and Mattson, M. P. (2011). Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol. 10, 187–198. doi: 10.1016/S1474-4422(10)70277-5
Knopman, D. S., Edland, S. D., Cha, R. H., Peterson, R. C., and Rocca, W. A. (2007). Incident dementia in women is preceded by weight loss by at least a decade. Neurology 69, 739–746. doi: 10.1212/01.wnl.0000267661.65586.33
Kolker, D. E., Fukuyama, H., Huang, D. S., Takahashi, J. S., Horton, T. H., and Turek, F. W. (2003). Aging alters circadian and light-induced expression of clock genes in golden hamsters. J. Biol. Rhythms 18, 159–169. doi: 10.1177/0748730403251802
Kornmann, B., Schaad, O., Bujard, H., Takahashi, J. S., and Schibler, U. (2007). System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. PLoS Biol. 5:e34. doi: 10.1371/journal.pbio.0050034
Kubo, T., Ozasa, K., Mikami, K., Wakai, K., Fujino, Y., Watanabe, Y., et al. (2006). Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. J. Epidemiol. 164, 549–555. doi: 10.1093/aje/kwj232
LeSauter, J., Hoque, N., Weintraub, M., Pfaff, D. W., and Silver, R. (2009). Stomach ghrelin-secreting cells as food-entrainable circadian clocks. Proc. Natl. Acad. Sci. U S A 106, 13582–13587. doi: 10.1073/pnas.0906426106
Liu, R.-Y., Zhou, J.-N., Hoogenduk, W. J. G., van Heerikuize, J., Kamphosrt, W., Unmehopa, U. A., et al. (2000). Decreased vasopressin gene expression in the biological clock of Alzheimer’s disease patients with and without depression. J. Neuropathol. Exp. Neurol. 59, 314–322.
Lutter, M., Sakata, I., Osborne-Lawrence, S., Rovinsky, S. A., Anderson, J. G., Jung, S., et al. (2008). The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat. Neurosci. 11, 752–753. doi: 10.1038/nn.2139
Maywood, E. S., Fraenkel, E., McAllister, C. J., Wood, N., Reddy, A. B., Hastings, M. H., et al. (2010). Disruption of peripheral circadian timekeeping in a mouse model of Huntington’s disease and its restoration by temporally scheduled feeding. J. Neurosci. 30, 10199–10204. doi: 10.1523/jneurosci.1694-10.2010
Mendoza, J., Angeles-Castellanos, M., and Escobar, C. (2005). Entrainment by a palatable meal induces food-anticipatory activity and c-Fos expression in reward-related areas of the brain. Neuroscience 133, 293–303. doi: 10.1016/j.neuroscience.2005.01.064
Merkestein, M., Brans, M. A. D., Luijendijk, M. C. M., de Jong, J. W., Egecioglu, E., Dickson, S. L., et al. (2012). Ghrelin mediates anticipation to a palatable meal in rats. Obesity (Silver Spring) 20, 963–971. doi: 10.1038/oby.2011.389
Mishima, K., Okawa, M., Hishikawa, Y., Hozumi, S., Hori, H., and Takahashi, K. (1994). Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr. Scand. 89, 1–7. doi: 10.1111/j.1600-0447.1994.tb01477.x
Mishima, K., Tozawa, T., Satoh, K., Matsumoto, Y., Hishikawa, Y., and Okawa, M. (1999). Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol. Psychiatry 45, 417–421. doi: 10.1016/s0006-3223(97)00510-6
Mistlberger, R. E., and Rusak, B. (1987). Palatable daily meals entrain anticipatory activity rhythms in free-feeding rats: dependence on meal size and nutrient content. Physiol. Behav. 41, 219–226. doi: 10.1016/0031-9384(87)90356-8
Mok, W. Y. W., Chu, L. W., Chung, C. P., Chan, N. Y., and Hui, S. L. (2004). The relationship between non-cognitive symptoms and functional impairment in Alzheimer’s disease. Int. J. Geriatr. Psychiatry 19, 1040–1046. doi: 10.1002/gps.1207
Moon, M., Choi, J. G., Nam, D. W., Hong, H.-S., Choi, Y.-J., Oh, M. S., et al. (2014). Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-β1-42 oligomer-injected mice. J. Alzheimers Dis. 23, 147–159. doi: 10.3233/JAD-2010-101263
Most, E. I. S., Scheltens, P., and Someren, E. J. W. (2012). Increased skin temperature in Alzheimer’s disease is associated with sleepiness. J. Neural. Transm. 119, 1185–1194. doi: 10.1007/s00702-012-0864-1
Naderali, E. K., Ratcliffe, S. H., and Dale, M. C. (2009). Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age. J. Alzheimer Dis. Other Demen. 24, 445–449. doi: 10.1177/1533317509348208
Otalora, B. B., Popovic, N., Gambini, J., Popovic, M., Viña, J., Bonet-Costa, V., et al. (2012). Circadian system functionality, hippocampal oxidative stress and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon. Chronobiol. Int. 29, 822–834. doi: 10.3109/07420528.2012.699119
Penev, P. D., Kolker, D. E., Zee, P. C., and Turek, F. W. (1998). Chronic circadian desynchronization decreases the survival of animals with cardiomyopathic heart disease. Am. J. Physiol. 275, H2334–H2337.
Proto, C., Romualdi, D., Cento, R. M., Spada, R. S., Di Mento, G., Ferri, R., et al. (2006). Plasma levels of neuropeptides in Alzheimer’s disease. Gynecol. Endocrinol. 22, 213–218. doi: 10.1080/09513590500519385
Rattan, S. I. (2010). “Synthesis, modification and turnover of proteins during aging,” in Protein Metabolism and Homeostasis in Aging, ed N. Tavernarakis (New York: Springer Science+Business Media), 1–13.
Rigamonti, A. E., Pincelli, A. I., Corra, B., Viarengo, R., Bonomo, S. M., Galimberti, D., et al. (2002). Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J. Endocrinol. 175, R1–R5. doi: 10.1677/joe.0.175r001
Singer, C., Tractenberg, R. E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., et al. (2003). A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 26, 893–901.
Spitznagel, M. B., Benitez, A., Updegraff, J., Potter, V., Alexander, T., Glickman, E., et al. (2010). Serum ghrelin is inversely associated with cognitive function in a sample of non-demented elderly. Psychiatry Clin. Neurosci. 64, 608–611. doi: 10.1111/j.1440-1819.2010.02145.x
Steen, E., Terman, M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., et al. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J. Alzheimers Dis. 7, 63–80.
Sterniczuk, R., Dyck, R. H., LaFerla, F. M., and Antle, M. C. (2010). Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes. Brain Res. 1348, 139–148. doi: 10.1016/j.brainres.2010.05.013
Stewart, R., Masaki, K., Xue, Q.-L., Peila, R., Petrovitch, H., White, L. R., et al. (2005). A 32-year prospective study of change in body weight and incident dementia. Arch. Neurol. 62, 55–60. doi: 10.1001/archneur.62.1.55
Stopa, E. G., Volicer, L., Kuo-Leblanc, V., Harper, D., Lathi, D., Tate, B., et al. (1999). Pathologic evaluation of the suprachiasmatic nucleus in severe dementia. J. Neuropathol. Exp. Neurol. 58, 29–39. doi: 10.1097/00005072-199901000-00004
Swaab, D. F., Fliers, E., and Partman, T. S. (1985). The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 342, 37–44. doi: 10.1016/0006-8993(85)91350-2
Szentirmai, E., Kapas, L., and Krueger, J. M. (2006). Ghrelin microinjection into forebrain sites induces wakefulness and feeding in rats. J. Physiol. Regul. Integr. Comp. Physiol. 292, R575–R585. doi: 10.1152/ajpregu.00448.2006
Szentirmai, E., Kapas, L., Sun, Y., Smith, R. G., and Krueger, J. M. (2010). Restricted feeding-induced sleep, activity and body temperature changes in normal and preproghrelin-deficient mice. J. Physiol. Regul. Integr. Comp. Physiol. 298, R467–R477. doi: 10.1152/ajpregu.00557.2009
Tabert, M. H., Liu, X., Doty, R. L., Serby, M., Zamora, D., Pelton, G. H., et al. (2005). A 10-item smell identification scale related to risk for Alzheimer’s disease. Ann. Neurol. 58, 155–160. doi: 10.1002/ana.20533
Tate, B., Aboody-Guterman, K. S., Morris, A. M., Walcott, E. C., Majocha, R. E., and Marotta, C. A. (1992). Disruption of circadian regulation by brain grafts that overexpress Alzheimer B/A4 amyloid. Proc. Natl. Acad. Sci. U S A 89, 7090–7094. doi: 10.1073/pnas.89.15.7090
Theodoropoulou, A., Metallinos, I. C., Psyrogiannis, A., Vagenakis, G. A., and Kyriazopoulou, V. (2012). Ghrelin and leptin secretion in patients with moderate Alzheimer’s disease. J. Nutr. Health Aging 16, 472–477. doi: 10.1007/s12603-012-0058-4
Toshinai, K., Yamaguchi, H., Sun, Y., Smith, R. G., Yamanaka, A., Sakurai, T., et al. (2006). Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 147, 2306–2314. doi: 10.1210/en.2005-1357
Tranah, G. J., Blackwell, T., Stone, K. L., Ancoli-Israel, S., Paudel, M. L., Ensrud, K. E., et al. (2011). Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann. Neurol. 70, 722–732. doi: 10.1002/ana.22468
Van Dam, D., D’Hooge, R., Staufenbiel, M., Van Ginneken, C., Van Meir, F., and De Deyn, P. P. (2003). Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17, 388–396. doi: 10.1046/j.1460-9568.2003.02444.x
van Someren, E. J. W., Hagebeuk, E. E. O., Lijzenga, C., Scheltens, P., de Rooiji, S. E. J. A., Jonker, C., et al. (1996). Circadian rest-activity rhythm disturbances in Alzheimer’s disease. Biol. Psychiatry 40, 259–270. doi: 10.1016/0006-3223(95)00370-3
Verhagen, L. A. W., Egecioglu, E., Luijendijk, M. C. M., Hillebrand, J. J. G., Adan, R. A. H., and Dickson, S. L. (2011). Acute and chronic suppression of the central ghrelin signaling system reveals a role in foodanticipatory activity. Eur. Neuropsychopharmacol. 21, 384–392. doi: 10.1016/j.euroneuro.2010.06.005
Vloeberghs, E., Van Dam, D., Engelborghs, S., Nagels, G., Staufenbiel, M., and De Deyn, P. P. (2004). Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur. J. Neurosci. 20, 2757–2766. doi: 10.1111/j.1460-9568.2004.03755.x
Wang, Q., Maillard, M., Schibler, U., Burnier, M., and Gachon, F. (2010). Cardiac hypertrophy, low blood pressure and low aldosterone levels in mice devoid of the three circadian PAR bZip transcription factors DBP, HLF and TEF. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1013–R1019. doi: 10.1152/ajpregu.00241.2010
Witting, W., Kwa, I. H., Eikelenboom, O., Mirimiran, M., and Swaab, D. F. (1990). Alterations in the circadian rest-activity rhythm in aging and Alzheimer’s disease. Biol. Psychiatry 27, 563–572. doi: 10.1016/0006-3223(90)90523-5
Witting, W., Mirmiran, M., Bos, N. P. A., and Swaab, D. F. (1994). The effect of old age on the free-running period of circadian rhythms in rat. Chronobiol. Int. 11, 103–112. doi: 10.3109/07420529409055896
Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., et al. (2000). The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141, 4325–4328. doi: 10.1210/en.141.11.4325
Wu, Y.-H., Zhou, J.-N., van Heerikhuize, J., Jockers, R., and Swaab, D. F. (2007). Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol. Aging 28, 1239–1247. doi: 10.1016/j.neurobiolaging.2006.06.002
Yamadera, H., Ito, T., Suzuki, H., Asayama, K., Ito, R., and Endo, S. (2000). Effects of bright light on cognitive and sleep-wake (circadian) rhythm disturbances in Alzheimer-type dementia. Psychiatry Clin. Neurosci. 54, 352–353. doi: 10.1046/j.1440-1819.2000.00711.x
Yamazaki, S., Numano, R., Abe, M., Hida, A., Takahashi, R.-I., Ueda, M., et al. (2000). Resetting central and peripheral circadian oscillators in transgenic rats. Science 288, 682–685. doi: 10.1126/science.288.5466.682
Yi, C.-X., Challet, E., Pévet, P., Kalsbeek, A., Escobar, C., and Buijs, R. M. (2008). A circulating ghrelin mimetic attenuates light-induced phase delay of mice and light-induced Fos expression in the suprachiasmatic nucleus of rats. Eur. J. Neurosci. 27, 1965–1972. doi: 10.1111/j.1460-9568.2008.06181.x
Yi, C.-X., van der Vliet, J., Dai, J., Yin, G., Ru, L., and Buijs, R. M. (2006). Ventromedial arcuate nucleus communicates peripheral metabolic information to the suprachiasmatic nucleus. Endocrinology 147, 283–294. doi: 10.1210/en.2005-1051
Keywords: circadian rhythms, Alzheimer’s disease, food-entrainment, ghrelin, aging
Citation: Kent BA (2014) Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer’s disease? Front. Aging Neurosci. 6:234. doi: 10.3389/fnagi.2014.00234
Received: 15 June 2014; Accepted: 15 August 2014;
Published online: 01 September 2014.
Edited by:Merce Pallas, University of Barcelona, Spain
Reviewed by:Nibaldo C. Inestrosa, Pontifical Catholic University of Chile, Chile
Merce Pallas, University of Barcelona, Spain
Copyright © 2014 Kent. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Brianne A. Kent, Department of Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK e-mail: firstname.lastname@example.org